Blueshift Asset Management LLC reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 56.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,616 shares of the medical research company's stock after selling 2,100 shares during the quarter. Blueshift Asset Management LLC's holdings in IQVIA were worth $318,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in IQV. Private Trust Co. NA lifted its position in IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock valued at $115,000 after acquiring an additional 47 shares in the last quarter. Pine Valley Investments Ltd Liability Co lifted its holdings in IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock worth $2,247,000 after acquiring an additional 50 shares during the period. Howard Capital Management Inc. increased its position in shares of IQVIA by 4.9% during the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after purchasing an additional 54 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock worth $1,068,000 after purchasing an additional 56 shares during the period. Finally, Cypress Wealth Services LLC boosted its holdings in shares of IQVIA by 4.8% in the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock worth $244,000 after buying an additional 57 shares during the last quarter. Institutional investors own 89.62% of the company's stock.
IQVIA Price Performance
Shares of IQV traded down $1.48 during trading hours on Wednesday, reaching $179.91. 1,316,671 shares of the company's stock traded hands, compared to its average volume of 1,242,599. IQVIA Holdings Inc. has a 12 month low of $179.16 and a 12 month high of $253.84. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market cap of $31.72 billion, a PE ratio of 23.99, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The firm's 50 day simple moving average is $194.24 and its 200-day simple moving average is $207.29.
IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on IQV. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. UBS Group decreased their target price on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Robert W. Baird dropped their price target on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 21st. William Blair reissued an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Finally, Bank of America dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a report on Friday, December 13th. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and an average target price of $249.05.
Read Our Latest Report on IQV
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
